Early COPERNICUS Safety and Administration-Related Reactions

Wade T. Iams, MD, of Tennessee Oncology, reviews early COPERNICUS safety data, in which patients receiving subcutaneous amivantamab plus lazertinib also received intensive skin prophylaxis. Compared descriptively with intravenous amivantamab in MARIPOSA, paronychia fell from 68% to 33%, rash from 62% to 24%, and venous thromboembolism from 37% to 9%, with far fewer grade 3 or higher skin events. Infusion-related reactions, above 60% with intravenous dosing, occurred in 0.9% of participants, none grade 3 or higher. Dr Iams says this mirrors his practice: his first 2 patients treated intravenously had infusion reactions, one ending up in the emergency department, while he has seen none with subcutaneous dosing, which lets him focus counseling on skin toxicity. Luis E. Raez, MD, of Miami Cancer Institute, notes that intravenous infusion reactions could tie up a chair all day, whereas subcutaneous dosing takes about 5 minutes and frees chairs so his center can treat more patients.